Sustainability of healthcare systems in the wake of COVID-19: The UK VPAS case study

Out of 1600+ accepted abstracts at ISPOR EU, Richard Macaulay's presentation has been identified as a Top 5% Finalist for the ISPOR Europe 2022 Research Presentation Awards. Richard's poster, entitled "Sustainability of Healthcare Systems in the Wake of COVID-19: The UK VPAS Case Study," was recognized for its scientific merit of research and unbiased presentation.

LEARN MORE

Sustainability of healthcare systems in the wake of COVID-19: The UK VPAS case study2023-05-09T14:35:41-04:00

Access90: Doug Hall

In this Access90, Precision’s Doug Hall discusses key lessons taken from the first NICE committee meeting to consider Upstaza for their highly specialized technology program for ultra-rare diseases.

LEARN MORE

Access90: Doug Hall2023-06-13T08:20:46-04:00

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)

Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.  

LEARN MORE

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)2023-02-20T20:59:08-05:00

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT

BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.

LEARN MORE

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT2023-02-20T21:02:41-05:00

On Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies

Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.

LEARN MORE

On Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies2023-02-20T21:07:39-05:00